Macuks R, Baidekalna I, Donina S
Riga Stradins University, A. Kirhenstein's Institute of Microbiology and Virology, Riga, Latvia.
Eur J Gynaecol Oncol. 2011;32(4):408-10.
The objective of the study was to evaluate the accuracy of a combined-two step ovarian cancer screening tool consisting of the ovarian cancer symptom index combined with either a risk of ovarian malignancy algorithm (ROMA) or a risk of malignancy index.
The case-control study consisted of 31 patients with ovarian cancer, 30 patients with benign ovarian diseases and 27 age-matched healthy controls.
Sensitivity and specificity of the ovarian cancer symptom index among menopausal women were 84.6% and 52.9%, respectively. ROMA revealed the highest discriminative value when compared to others (AUC 98.4%). When the cutoff level of 28 was applied for menopausal women, ROMA revealed sensitivity and specificity of 95.8% and 93.1%, respectively.
The ovarian cancer symptom index could be used as the first step in ovarian cancer screening with subsequent application of ROMA as a second step screening tool. A larger sample size in both control and patient groups should be evaluated to reach clear conclusions.
本研究的目的是评估一种两步联合的卵巢癌筛查工具的准确性，该工具由卵巢癌症状指数与卵巢恶性肿瘤风险算法（ROMA）或恶性肿瘤风险指数组成。
病例对照研究包括31例卵巢癌患者、30例良性卵巢疾病患者和27例年龄匹配的健康对照。
绝经后女性中卵巢癌症状指数的敏感性和特异性分别为84.6%和52.9%。与其他方法相比，ROMA显示出最高的鉴别价值（曲线下面积98.4%）。当对绝经后女性应用28的临界值时，ROMA的敏感性和特异性分别为95.8%和93.1%。
卵巢癌症状指数可作为卵巢癌筛查的第一步，随后应用ROMA作为第二步筛查工具。应评估更大样本量的对照组和患者组以得出明确结论。
